A 4-week Study Investigating Two Targeted Brightening Serum (A and B) Versus 4% Hydroquinone in Women With Mild to Severe Full-face Hyperpigmentation

Part of paid clinical trials in Irving, Texas.

Sponsor
Revision Skincare
Study ID
NCT07644871
Status
Completed

Conditions

  • Dark Spots
  • Hyperpigmentation
  • Melasma

Eligibility Criteria

Sex
FEMALE
Age
20 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • Facial Cleanser — OTHER
    Gentle Foaming Cleanser to wash the face two times a day (am/pm)
  • Facial Moisturizer — OTHER
    Basic Moisturizer applied in the evening after the treatment (brightening serum a, or b or the 4% HQ).
  • Sunscreen SPF 55 — OTHER
    Neutrogena Ultra Sheer Dry-Touch Sunscreen SPF 55 applied in the am as the last step

Study Details

This a short four-week pilot study to measure the efficacy and tolerance of two brightening serums (cosmetics) versus 4% hydroquinone. The study was conducted in two sites across the USA, one in PA and in one in CA. The goal was to run the pilot study in the summer to understand the role of these two potential brightening serums in helping the appearance of skin tone evenness.

Key Dates

Start date
Aug 11, 2025
Status verified
Jun 2026
Primary completion
Nov 12, 2025
Completion
Nov 12, 2025

Study Design

Enrollment
18 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Brightening Serum A
    The brightening serum A is a hydroquinone-free serum containing botanical ingredients, brightening ingredients such as tranexamoyl Dipeptide-23, niacinamide, vitamin C, diacetyl boldine, antioxidants and microbiome technology to help reduce skin pigmentation.
  • Active Comparator: Brightening Serum B
    The brightening serum B is a hydroquinone-free serum containing botanical ingredients, brightening ingredients such as tranexamic acid, niacinamide, vitamin C, diacetyl boldine, antioxidants and microbiome technology to help reduce skin pigmentation.
  • Other: 4% Hydroquinone
    This topical 4% hydroquinone cream was applied split-face to side randomized for application.

Primary Outcome Measure

Measurement of Clinical Efficacy Parameters by Clinical Grader [ Time Frame: Baseline, week 2, week 4 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Revision SkincareIrvingTexas75063-

Find similar trials in Irving, TX

By research site
Revision Skincare· Irving, TX

Related Studies